Literature DB >> 17904324

Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: comparison of integrated PET/CT with or without contrast enhancement.

Tsuyoshi Morimoto1, Ukihide Tateishi, Tetsuo Maeda, Yasuaki Arai, Yasuo Nakajima, E Edmund Kim.   

Abstract

AIM: To determine the diagnostic accuracy of integrated contrast-enhanced positron emission tomography (PET) and computed tomography (CT), as compared with non-contrasted PET/CT, in evaluating nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways.
MATERIALS AND METHODS: Sixty-six patients (33 men and 33 women) with malignant lymphoma underwent staging with integrated CT and fluorine-18-fluorodeoxyglucose ((18)FDG) PET. Tumor types were diffuse large B-cell lymphoma (n=26, 39%), follicular lymphoma (n=20, 30%), Hodgkin disease (n=16, 24%), and marginal zone B-cell lymphoma (n=4, 6%). Both non-contrasted PET/CT and contrast-enhanced PET/CT images were examined separately by two different qualified physicians for each imaging modality, and nodal status of pelvic and retroperitoneal lymphatic pathways was evaluated. Reference standard included follow-up with clinical, laboratory, and conventional CT findings. We compared diagnostic accuracy retrospectively on basis of per-patient and per-lesion analyses between two modalities using McNemar test, respectively.
RESULTS: Nodal status of pelvic and retroperitoneal lymphatic pathways was more accurately determined on contrast-enhanced PET/CT (n=52, 79%) compared with non-contrasted PET/CT (n=47, 71%). Difference in the accuracy of nodal staging between non-contrasted PET/CT and contrast-enhanced PET/CT was significant (p=0.048). On basis of per-lesion analysis, contrast-enhanced PET/CT determined more accurately the status of external iliac lymph node (p=0.002), internal iliac lymph node (p<0.0001), and common iliac lymph node (p=0.002) compared with non-contrasted PET/CT. Diagnostic accuracies of paraaortic lymph node, aortocaval lymph node, and paracaval lymph node were similar by either non-contrasted PET/CT or contrast-enhanced PET/CT.
CONCLUSION: Integrated contrast-enhanced PET/CT improves the diagnostic accuracy in evaluating nodal status of pelvic and retroperitoneal lymphatic pathways in patients with malignant lymphoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904324     DOI: 10.1016/j.ejrad.2007.08.017

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  4 in total

1.  Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging.

Authors:  Philip Aschoff; Christian Plathow; Thomas Beyer; Matthias P Lichy; Gunter Erb; Mehmet Ö Öksüz; Claus D Claussen; Christina Pfannenberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-29       Impact factor: 9.236

2.  Radiation dose reduction through combining positron emission tomography/computed tomography (PET/CT) and diagnostic CT in children and young adults with lymphoma.

Authors:  Zhihua Qi; Erica L Gates; Maureen M O'Brien; Andrew T Trout
Journal:  Pediatr Radiol       Date:  2017-10-28

3.  Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence.

Authors:  Kazuhiro Kitajima; Kayo Suzuki; Yuji Nakamoto; Yumiko Onishi; Setsu Sakamoto; Michio Senda; Masato Kita; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-13       Impact factor: 9.236

4.  Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT.

Authors:  Agostino Chiaravalloti; Roberta Danieli; Cristiana Ragano Caracciolo; Laura Travascio; Maria Cantonetti; Andrea Gallamini; Manlio Guazzaroni; Antonio Orlacchio; Giovanni Simonetti; Orazio Schillaci
Journal:  Medicine (Baltimore)       Date:  2014-08       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.